乳腺癌——PTEN缺失预示着治疗耐药。 - Suppr

Suppr

超能文献

Breast cancer--loss of PTEN predicts resistance to treatment.

作者信息

Pandolfi Pier Paolo

机构信息

Cancer Biology and Genetics Program, Memorial-Sloan Kettering Cancer Center, New York, USA.

出版信息

N Engl J Med. 2004 Nov 25;351(22):2337-8. doi: 10.1056/NEJMcibr043143.

DOI:10.1056/NEJMcibr043143

PMID:15564551

Abstract

摘要

相似文献

Breast cancer--loss of PTEN predicts resistance to treatment.

N Engl J Med. 2004 Nov 25;351(22):2337-8. doi: 10.1056/NEJMcibr043143.

Successful targeting of ErbB2 receptors-is PTEN the key?

Cancer Cell. 2004 Aug;6(2):103-4. doi: 10.1016/j.ccr.2004.08.001.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Cancer Cell. 2004 Aug;6(2):117-27. doi: 10.1016/j.ccr.2004.06.022.

PTEN activation may contribute to exquisite antitumor response to trastuzumab.

Breast. 2005 Apr;14(2):175; author reply 176. doi: 10.1016/j.breast.2004.09.009.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Cancer Cell. 2007 Oct;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030.

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Nat Clin Pract Oncol. 2006 May;3(5):269-80. doi: 10.1038/ncponc0509.

PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?

Cancer Cell. 2007 Oct;12(4):297-9. doi: 10.1016/j.ccr.2007.10.004.

Trastuzumab: mechanisms of resistance and therapeutic opportunities.

Oncology (Williston Park). 2008 Oct;22(11):1250-8; discussion 1259, 1263.

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Bull Cancer. 2007 Mar;94(3):259-66.

Mechanisms of trastuzumab resistance and their clinical implications.

Ann N Y Acad Sci. 2005 Nov;1059:70-5. doi: 10.1196/annals.1339.026.

引用本文的文献

Semaphorin 3F inhibits breast cancer metastasis by regulating the Akt-mTOR and TGFβ signaling pathways via neuropilin-2.

Sci Rep. 2025 Mar 3;15(1):7394. doi: 10.1038/s41598-025-91559-y.

HER2-Positive Breast Cancer Treatment and Resistance.

Adv Exp Med Biol. 2025;1464:495-525. doi: 10.1007/978-3-031-70875-6_24.

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.

Cancers (Basel). 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138.

Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy.

Acta Pharm Sin B. 2023 Mar;13(3):955-966. doi: 10.1016/j.apsb.2022.09.021. Epub 2022 Oct 4.

Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment.

Diagnostics (Basel). 2022 Feb 3;12(2):394. doi: 10.3390/diagnostics12020394.

The PTEN and ATM axis controls the G1/S cell cycle checkpoint and tumorigenesis in HER2-positive breast cancer.

Cell Death Differ. 2021 Nov;28(11):3036-3051. doi: 10.1038/s41418-021-00799-8. Epub 2021 May 31.

Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis.

J Cancer. 2021 Jan 18;12(6):1687-1697. doi: 10.7150/jca.51845. eCollection 2021.

Neddylation blockade induces HIF-1α driven cancer cell migration via upregulation of ZEB1.

Sci Rep. 2020 Oct 23;10(1):18210. doi: 10.1038/s41598-020-75286-0.

Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.

Theranostics. 2020 Sep 2;10(24):11092-11109. doi: 10.7150/thno.44997. eCollection 2020.

Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives.

Cancers (Basel). 2019 Sep 19;11(9):1401. doi: 10.3390/cancers11091401.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验